VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.85%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$20.5M
(-9.7%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-6.22%
Top 10 Holdings %
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125
Top Buys
| 1 |
Brookfield Infrastructure
BIPC
|
$1.15M |
| 2 |
ECC
Eagle Point Credit Co
ECC
|
$1.05M |
| 3 |
OXLC
Oxford Lane Capital
OXLC
|
$1.03M |
| 4 |
ORAN
Orange
ORAN
|
$395K |
| 5 |
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
|
$391K |
Top Sells
| 1 |
Delek Logistics
DKL
|
$2.05M |
| 2 |
Western Midstream Partners
WES
|
$788K |
| 3 |
CNXM
CNX Midstream Partners LP
CNXM
|
$744K |
| 4 |
OSB
Norbord Inc.
OSB
|
$657K |
| 5 |
Lamar Advertising Co
LAMR
|
$515K |
Sector Composition
| 1 | Healthcare | 32.34% |
| 2 | Real Estate | 18.02% |
| 3 | Energy | 12.43% |
| 4 | Materials | 10.7% |
| 5 | Financials | 6.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
BioNTech
BNTX
$27B
| $441K | 0.23% |
6,363
-849
| -12% | -$58.8K |
|
|
TPTX
152
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $440K | 0.23% |
5,034
-694
| -12% | -$60.7K |
|
153
Agios Pharmaceuticals
AGIO
$2.09B
| $434K | 0.23% |
12,398
+1,044
| +9% | +$36.5K |
|
154
CRISPR Therapeutics
CRSP
$4.99B
| $431K | 0.23% |
5,155
-689
| -12% | -$57.6K |
|
|
KIO
155
KKR Income Opportunities Fund
KIO
$514M
| $430K | 0.23% |
31,779
-21,338
| -40% | -$289K |
|
156
Atara Biotherapeutics
ATRA
$90.7M
| $426K | 0.22% |
1,314
-180
| -12% | -$58.4K |
|
157
Goldman Sachs BDC
GSBD
$1.31B
| $425K | 0.22% |
28,237
-1,654
| -6% | -$24.9K |
|
158
BioMarin Pharmaceuticals
BMRN
$11.1B
| $421K | 0.22% |
5,529
+466
| +9% | +$35.5K |
|
159
Golub Capital BDC
GBDC
$3.93B
| $420K | 0.22% |
31,732
-13,144
| -29% | -$174K |
|
160
Xencor
XNCR
$610M
| $420K | 0.22% |
10,833
-1,492
| -12% | -$57.8K |
|
161
Zymeworks
ZYME
$1.14B
| $420K | 0.22% |
9,021
-1,227
| -12% | -$57.1K |
|
162
Ares Capital
ARCC
$15.8B
| $414K | 0.22% |
29,644
-2,935
| -9% | -$41K |
|
|
MRNS
163
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $414K | 0.22% |
32,237
-4,403
| -12% | -$56.5K |
|
164
Rigel Pharmaceuticals
RIGL
$742M
| $411K | 0.22% |
17,124
-2,334
| -12% | -$56K |
|
165
Arrowhead Research
ARWR
$4.02B
| $406K | 0.21% |
9,424
-1,281
| -12% | -$55.2K |
|
166
Omeros
OMER
$284M
| $404K | 0.21% |
39,936
+3,363
| +9% | +$34K |
|
167
BridgeBio Pharma
BBIO
$10.2B
| $403K | 0.21% |
10,753
-1,458
| -12% | -$54.6K |
|
168
Sixth Street Specialty
TSLX
$2.32B
| $403K | 0.21% |
23,406
-2,143
| -8% | -$36.9K |
|
|
EPZM
169
DELISTED
Epizyme, Inc
EPZM
| $402K | 0.21% |
33,686
+2,837
| +9% | +$33.9K |
|
170
Fate Therapeutics
FATE
$116M
| $401K | 0.21% |
10,028
-1,361
| -12% | -$54.4K |
|
171
TriplePoint Venture Growth BDC
TPVG
$275M
| $401K | 0.21% |
36,328
-42,204
| -54% | -$466K |
|
|
ITCI
172
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $393K | 0.21% |
15,303
-2,089
| -12% | -$53.6K |
|
173
Akero Therapeutics
AKRO
$3.58B
| $391K | 0.21% |
12,686
-1,739
| -12% | -$53.6K |
|
174
Rocket Pharmaceuticals
RCKT
$354M
| $389K | 0.2% |
16,995
-2,315
| -12% | -$53K |
|
175
MacroGenics
MGNX
$126M
| $388K | 0.2% |
15,384
-2,100
| -12% | -$53K |
|